Insider Buying: Ralliant (NYSE:RAL) SVP Buys $99,942.15 in Stock

Ralliant Corporation (NYSE:RAL) SVP Amir Kazmi bought 2,545 shares of the company’s stock in a transaction on Friday, February 6th. The shares were acquired at an average price of $39.27 per share, with a total value of $99,942.15. Following the transaction, the senior vice president directly owned 39,699 shares in the company, valued at approximately $1,558,979.73. The trade was a 6.85% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

Ralliant Stock Down 0.6%

Shares of Ralliant stock opened at $42.78 on Thursday. The business has a fifty day simple moving average of $51.11 and a 200 day simple moving average of $46.62. The stock has a market cap of $4.83 billion and a PE ratio of 21.83. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.38. Ralliant Corporation has a 12 month low of $37.27 and a 12 month high of $57.02.

Ralliant (NYSE:RAL) last issued its earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.02. The company had revenue of $554.60 million for the quarter, compared to the consensus estimate of $543.04 million. The business’s quarterly revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 23rd. Shareholders of record on Monday, March 9th will be issued a $0.05 dividend. The ex-dividend date is Monday, March 9th. This represents a $0.20 annualized dividend and a yield of 0.5%. Ralliant’s dividend payout ratio (DPR) is 10.20%.

Hedge Funds Weigh In On Ralliant

Large investors have recently bought and sold shares of the company. Danske Bank A S bought a new position in shares of Ralliant during the 4th quarter worth approximately $25,000. Westfuller Advisors LLC acquired a new position in Ralliant during the third quarter worth $26,000. V Square Quantitative Management LLC bought a new position in Ralliant in the fourth quarter valued at $26,000. Allworth Financial LP increased its stake in Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after buying an additional 293 shares during the last quarter. Finally, Palisade Asset Management LLC bought a new stake in Ralliant during the 3rd quarter worth about $26,000.

Ralliant News Summary

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Company insiders (directors and an SVP) bought shares this week, signaling management confidence and providing a support signal for some investors. Insider Buying Alert
• Positive Sentiment: Vertical Research upgraded RAL (reported by media), which can attract buyers and help stabilize demand. Vertical Research Upgrade
• Neutral Sentiment: Ralliant will present at Citi and Barclays investor conferences Feb. 17–18 — management may use these forums to clarify impairment drivers and outlook (could reduce uncertainty if handled well). Investor Conference Notice
• Neutral Sentiment: Some sell‑side firms trimmed price targets (Barclays, Citi, Oppenheimer et al.) — mixed analyst adjustments leave consensus still above current levels but reduce near‑term enthusiasm. Analyst Target Moves
• Negative Sentiment: Ralliant disclosed a $1.4B non‑cash goodwill impairment in its Test & Measurement segment and trimmed FY‑2026 guidance — a material accounting charge that directly pressured the stock and prompted analyst downgrades. Impairment / Guidance Notice
• Negative Sentiment: Multiple law firms (Levi & Korsinsky, Kessler Topaz, Kaplan Fox, Kirby McInerney, Bragar Eagel & Squire, etc.) have opened investigations into the timing and disclosure around the impairment and dividend — this raises litigation, regulatory and reputational risk. Levi & Korsinsky Alert
• Negative Sentiment: Short interest jumped ~58.7% in January (~3.75M shares, ~3.3% of float), increasing bearish positioning that can amplify downside and intraday volatility.
• Negative Sentiment: Independent downgrades (e.g., Zacks strong‑sell, Weiss Ratings cut) add selling pressure and can limit buyers until uncertainty eases. Zacks

Analysts Set New Price Targets

Several research analysts have weighed in on RAL shares. Vertical Research upgraded Ralliant from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a report on Friday, February 6th. Truist Financial cut their price objective on Ralliant from $62.00 to $49.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Weiss Ratings cut Ralliant from a “hold (c)” rating to a “sell (d)” rating in a research note on Thursday, February 5th. Citigroup dropped their target price on shares of Ralliant from $61.00 to $51.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Finally, Oppenheimer reduced their price target on shares of Ralliant from $60.00 to $50.00 and set an “outperform” rating for the company in a report on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $50.50.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.